Two people infected with the same strain of COVID-19 can have vastly different experiences. One might never even sniffle, and ...
Eli Lilly-partnered TRexBio will apply the IPO proceeds toward clinical development of molecules designed to activate regulatory T cells to mediate immune responses and inflammation. Meanwhile, ...
Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support ...
Researchers have built the first cross-tissue single-cell atlas of T cell and B cell receptor repertoires in healthy piglets, ...
Novartis bought an mRNA-coded autoimmune T-cell engager candidate for up to $7.8 billion, as Shionogi offered $2 billion to ...
CytoMed Therapeutics Limited (the “Company”) (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable ...
CellFiber Co., Ltd., a Tokyo-based biotechnology company developing 3D cell culture and bioprocessing technology for ...
As the standards of care for prostate cancer change, new drugs, combination therapies, and trials enter the therapeutic space ...
Basic studies led to clinical and translational advances that no one could have predicted,” Robert Gallo writes of his work ...
New EG95-based mRNA-lipid nanoparticle vaccines induced stronger and longer-lasting immunity against cystic echinococcosis ...
Urine cell-free (cf)RNA analysis could represent a promising biomarker for bladder cancer, according to a study published online Oct. 2 in Nature Medicine. Kevin J. Liu, PhD, from Stanford University ...
A bid-price notice does not delist a stock - it starts a clock, and CytoMed has until next April to run out the compliance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results